Products
Online Inquiry
CCG 203769
Cat. No.:
OB0225WX-2071
Appearance:
Liquid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
CCG 203769 is a selective small molecule inhibitor of RGS4 that disrupts the RGS4-Gao protein-protein interaction with an IC50 of 17 nM.
Synonym:
4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione; RGS4 inhibitor 11b; Thiadiazolidinone (TDZD) deriv. 6; 410074-60-1; CCG 203769; 2-ethyl-4-butyl-1,2,4-thiadiazolidine-3,5-dione; 4-n-Butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione
CAS No.:
410074-60-1
Compound CID:
6539137
Formula:
C8H14N2O2S
Formula Weight:
202.27
Specification
Targets&IC50:
RGS19: 140 nM; GSK-3β: 5.4 μM; RGS4: 17 nM; RGS8: 79 μM; RGS16: 6 μM
Relative Density:
1.179 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CCG 203769 is utilized in signal transduction research as a selective RGS4 inhibitor to study the modulation of G-protein coupled receptor signaling and its impact on dopaminergic pathways.
Library Information
Target:
GSK-3; Dopamine receptor; GTPase
Receptor:
RGS4; RGS19; RGS16; RGS8; GSK-3β; D2 receptor
Pathways:
Stem cells; GPCR/G protein signaling; Neuronal signaling; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-27
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 247.2 mM
